Table 2.
Characteristics of patients with TA and GCA at the time of PET/MRI.
| All (GCA + TA) (n = 13, 18 scans) | GCA (n = 7, 8 scans) | TA (n = 6, 10 scans) | P value (GCA vs TA) | |
|---|---|---|---|---|
| Vascular signs | 7/18 (39%) | 3/8 (38%) | 4/10 (40%) | 0.7 |
| Constitutional symptoms | 8/18 (44%) | 6/8 (75%) | 2/10 (20%) | 0.01 |
| C-reactive protein level (mg/L) | 23 [0–250] | 25.5 [0–250] | 7.5 [0–100] | 0.2 |
| PET/MRI inflammatory pattern | 8/18 (44%) | 3/8 (17%) | 5/10 (50%) | 0.6 |
| PET/MRI fibrous pattern | 3/18 (17%) | 0/8 (0%) | 3/10 (30%) | 0.2 |
| PET/MRI normal | 7/18 (39%) | 5/8 (62.5%) | 2/10 (20%) | 0.3 |
| SUVmax | 3.0 [1.8–8.6] | 3.4 [2.1–8.6] | 2.6 [1.8–7.1] | 0.4 |
| FDG uptake with polymyalgia rheumatica | 2/18 | 2/8 (25%) | NA | — |
| MRI arterial thickening (>2 mm) | 10 (61%) | 2/8 (25%) | 8/10 (80%) | 0.05 |
| MRI stenosis | 6/18 (33%) | 0/8 | 6/10 (60%) | 0.01 |
| Active disease (clinical and/or biological signs) | 11/18 (61%) | 6/8 (75%) | 5/10 (50%) | 0.4 |
| Steroids at the time of PET/MRI | 10/18 (56%) | 6/8 (75%) | 4/10 (40%) | 0.4 |
| Steroids (mg/day) | 30 [3–240] | 50 [15–240] | 12.5 [3–45] | 0.005 |
| Time between steroid initiation and PET/MRI (months) | 28 [0–518] | 28 [0–518] | 53 [0–121] | 0.9 |
| Time between diagnosis and PET/MRI (months) | 44 [0–222] | 14 [0–61] | 86 [4–222] | 0.004 |
Data are median [range], or n (%).